Cellectis (CLLS) Capital Expenditures Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 143.40% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 32.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.91% |
| Dec 31, 2025 | -59.25% |
| Sep 30, 2025 | -51.99% |
| Jun 30, 2025 | 70.62% |
| Mar 31, 2025 | -81.19% |
| Dec 31, 2024 | 479.17% |
| Sep 30, 2024 | -147.45% |
| Jun 30, 2024 | -284.44% |
| Mar 31, 2024 | -2.35% |
| Dec 31, 2023 | -81.97% |
| Sep 30, 2023 | 29.91% |
| Jun 30, 2023 | 70.49% |
| Mar 31, 2023 | 65.97% |
| Dec 31, 2022 | -87.99% |
| Sep 30, 2022 | 90.29% |
| Jun 30, 2022 | 83.21% |
| Mar 31, 2022 | 92.36% |
| Dec 31, 2021 | -49.11% |
| Sep 30, 2021 | 27.18% |
| Jun 30, 2021 | 61.01% |
| Mar 31, 2021 | -3.53% |
| Dec 31, 2020 | 211.78% |
| Sep 30, 2020 | -15.90% |
| Jun 30, 2020 | -366.12% |
| Mar 31, 2020 | -336.64% |
| Dec 31, 2019 | 225.06% |
| Sep 30, 2019 | -343.31% |
| Jun 30, 2019 | -444.28% |
| Mar 31, 2019 | -185.35% |
| Dec 31, 2018 | 67.86% |
| Sep 30, 2018 | -110.41% |
| Jun 30, 2018 | 45.17% |
| Mar 31, 2018 | -16.30% |
| Dec 31, 2017 | -83.82% |
| Sep 30, 2017 | 76.37% |
| Jun 30, 2017 | 63.08% |
| Mar 31, 2017 | 92.53% |
| Dec 31, 2016 | 4,273.74% |
| Sep 30, 2016 | -1,166.93% |
| Jun 30, 2016 | -523.52% |
| Mar 31, 2016 | -135.73% |